Heart Disease in Women: The Cardiac Amyloid Blind Spot That Delays Diagnosis by Years
A new review finds that women with transthyretin amyloid cardiomyopathy face diagnostic delays of up to five years because sex-blind ...
Tag: transthyretin amyloid cardiomyopathy
Tafamidis Tied to 74% Lower Death Risk in Matched Real-World Heart Amyloidosis Cohort
A matched real-world cohort analysis found that patients with transthyretin amyloid cardiomyopathy treated with tafamidis had a 74% lower risk ...
Tafamidis Helps More Heart Amyloid Patients Keep Their Walking Distance, Analysis Finds
A post hoc analysis of the ATTR-ACT trial found that 64 percent of tafamidis-treated patients maintained walking-distance stability at 12 ...
Tafamidis Cuts Cardiovascular Death and Hospitalization Risk for Up to 90 Months
A post hoc analysis of the ATTR-ACT trial and its long-term extension found continuous tafamidis treatment significantly reduced cardiovascular death ...
Early TTR Rise on Tafamidis Tied to Lower Death Risk in ATTR-CM Trial Analysis
A post hoc analysis of the ATTR-ACT trial found that early increases in TTR concentration after tafamidis treatment were associated ...
Women Remain a Small Minority in Tafamidis-Treated Amyloid Heart Disease Cohort
A pooled analysis of 1924 tafamidis-treated patients found women made up 11.1 percent of the cohort, more often carried hereditary ...
Research report: Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy
A pooled real-world analysis of 1,924 patients with transthyretin amyloid cardiomyopathy treated with tafamidis found that outcomes in patients aged ...
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development